Who Paid My Doc
Michael Kazak
Geriatric Medicine Santa Maria, CA Medical Doctor
NPI 1285732636 CMS profile 330759
1040 W Main St, Santa Maria, CA 93458
General payments
$519
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Michael Kazak of Santa Maria, CA is reported in the CMS Open Payments database as having received $519 across 24 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 67th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $103 | 4 | |
| 2023 | General | $29 | 1 | |
| 2021 | General | $23 | 2 | |
| 2020 | General | $68 | 4 | |
| 2019 | General | $296 | 13 |
Beside peers
- Michael Kazak
- Geriatric Medicine median
- Middle half of Geriatric Medicine
- National median
In program year 2025, general payments to Michael Kazak were reported at $103. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.
Show as a table
| Year | Michael Kazak | Geriatric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $296 | $122 | $40–$435 | $163 |
| 2020 | $68 | $98 | $25–$349 | $114 |
| 2021 | $23 | $125 | $34–$441 | $132 |
| 2022 | $0 | $124 | $36–$408 | $149 |
| 2023 | $29 | $121 | $41–$383 | $160 |
| 2024 | $0 | $134 | $41–$435 | $164 |
| 2025 | $103 | $123 | $35–$408 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 159 drugsPart D claims
16,227
Drug cost
$753,766
Branded share of claims
15.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Januvia Sitagliptin Phosphate | Brand | 133 | $136,745 | |
| Farxiga Dapagliflozin Propanediol | Brand | 111 | $78,322 | |
| Xarelto Rivaroxaban | Brand | 70 | $71,098 | |
| Eliquis Apixaban | Brand | 67 | $61,443 | |
| Ozempic Semaglutide | Brand | 43 | $49,708 | |
| Jardiance Empagliflozin | Brand | 53 | $41,792 | |
| Janumet Sitagliptin Phos/Metformin Hcl | Brand | 35 | $41,046 | |
| Tradjenta Linagliptin | Brand | 16 | $22,440 | |
| Janumet Xr Sitagliptin Phos/Metformin Hcl | Brand | 16 | $21,206 | |
| Vraylar Cariprazine Hcl | Brand | 12 | $16,931 |
The 10 drugs with the highest cost, of 159 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 26 billing codesPaid by Medicare
$184,886
Medicare patients
474
Services billed
3,006
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 46% | |
| Arthritis | 29% | |
| Chronic kidney disease | 23% | |
| Ischemic heart disease | 20% | |
| COPD | 17% | |
| Atrial fibrillation | 11% | |
| Depression | 11% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 | Office | 137 | 140 | $3,066 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 101 | 171 | $117 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 63 | 192 | $94 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 14 | 16 | $15 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
24 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Geriatric Medicine in California
Related records
Geriatric Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Geriatric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.